Format

Send to:

Choose Destination
See comment in PubMed Commons below
Gynecol Obstet Fertil. 2006 Jul-Aug;34(7-8):593-6. Epub 2006 Jun 30.

[Efavirenz (Sustiva) in pregnancy: a study about 12 HIV patients].

[Article in French]

Author information

  • 1Service des maladies infectieuses, hôpital Jean-Verdier (AP-HP), Seine-Saint-Denis, avenue du 14-Juillet, 93140 Bondy, France. vincent.jeantils@jvr.aphp.fr

Abstract

OBJECTIVE:

In developed countries, where the mother-to-child transmission rate of HIV is low (1 to 1,5%), a major medical concern is the safety of new therapies during pregnancy. Teratogenicity has been described with an NNRTI, efavirenz (Sustiva), in animal model, regarding neural tube defects.

PATIENTS AND METHODS:

We have made a retrospective study of pregnancies starting with efavirenz with a special focus on foetal and infant abnormalities.

RESULTS:

Three abnormalities were notified no one linked to a neural tube defect.

DISCUSSION AND CONCLUSION:

In the English literature published, although the prevalence of abnormalities in human is low (1,7%) during pregnancy, due to the potent teratogenicity, efavirenz is contraindicated in the first trimester and should be used with caution in women of childbearing potential.

PMID:
16814587
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk